Some of the emails to Fauci at the beginning of the pandemic turned out to be eerily prophetic as thousands reached out to him for advice or with suggestions.
"These prices can go to unimaginable highs before they settle down to a reasonable valuation," Interactive Brokers' Thomas Peterffy told CNBC on Monday.
Biogen CEO Michel Vounatsos told CNBC that the list price of $56,000 per year for the company's FDA-approved Alzheimer's disease drug aducanumab is "fair."
The U.S. is reporting an average of about 14,500 daily infections over the past week, as average daily cases have held below 15,000 for three days straight.
Consumer behavior is always evolving, but not in a monolithic way, especially after the pandemic, says Wharton marketing and psychology professor Deborah Small.
Even before the pandemic, the World Bank estimated it could take 150 years for women to achieve gender equality. The crisis has likely extended that timeline.
Amazon has big health care ambitions, yet the CEO of virtual medicine Teladoc, which has seen its booming share price halved, isn't worried. Should he be?